Back to User profile » Dr Mark Bergmann
Papers published by Dr Mark Bergmann:
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P
Clinical Ophthalmology 2021, 15:129-140
Published Date: 12 January 2021
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G
Clinical Ophthalmology 2017, 11:1089-1097
Published Date: 8 June 2017
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
Torkildsen G, Narvekar A, Bergmann M
Clinical Ophthalmology 2015, 9:1703-1713
Published Date: 14 September 2015
Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
Bergmann MT, Williams JI, Gomes PJ
Clinical Ophthalmology 2014, 8:1495-1505
Published Date: 13 August 2014